Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
Matrixyl (Palmitoyl Pentapeptide): Regulatory Status
Current legal and regulatory status for Matrixyl (Palmitoyl Pentapeptide) across jurisdictions. This page reflects the most recent verified information and is updated as regulatory actions occur.
Back to Matrixyl (Palmitoyl Pentapeptide) overviewUnited States
?
Gray Area
Compounding status: not applicable (cosmeceutical). WADA: not listed. globally marketed cosmeceutical; one of the most well-studied anti-aging peptides
Last verified:
What This Means
Reclassification is not the same as FDA approval.
Even if Matrixyl (Palmitoyl Pentapeptide) moves to Category 1, it remains an off-label therapeutic that requires physician supervision. Category 1 means it can be compounded under section 503A — it does not confer approved-drug status.